'More Is Not Better' in Two First-Line Trials for Biliary Tract Cancer

MedPage Today) — SAN FRANCISCO — More therapy, whether cytotoxic or targeted, failed to improve outcomes in two separate randomized trials of front-line treatment for advanced biliary-tract cancer.
The SWOG 1815 trial showed that adding nab…
Read More

What's Hot

Business Maverick: China industrial profits drop on weak demand, falling prices

No ‘decoupling’ here: Apple, Samsung, and Qualcomm sing China’s praises

Covid-19: India reports 1,805 new cases in 24 hours; daily positivity rate at 3.19 per cent

‘More Is Not Better’ in Two First-Line Trials for Biliary Tract Cancer

Trenton Educational Foundation Teacher Grants are making a Difference

MRI-Guided RT Reduced Acute Toxic Effects in Men With Localized Prostate Cancer

The Week Unwrapped: Antisocial Saudis, hormone therapy and retro tech

FDA okays first human stool therapy

Business Maverick: China industrial profits drop on weak demand, falling prices

No ‘decoupling’ here: Apple, Samsung, and Qualcomm sing China’s praises

Covid-19: India reports 1,805 new cases in 24 hours; daily positivity rate at 3.19 per cent

New downtown exhibit compares Winnipeg’s COVID-19 response to the Spanish Flu

Covid returns? India reports highest daily cases in nearly five months; active cases at 9,433

Wastewater could be used to track more viruses than COVID-19

Police require protesters to wear number badges

Cameron Toshack interview: What really happened at Leeds United, dad’s Covid fight and my Swansea City pride

A message to our readers: we’re here to stay

Anubhav Sinha: Showing lockdown-Partition similarities 'deeply personal'

What's Hot

‘More Is Not Better’ in Two First-Line Trials for Biliary Tract Cancer

Related Posts